TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05823480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allo HCT per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow biopsy and aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06514326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPT-TP
Description: This intervention includes all the ingredients of DPT-STD, but with additional features that correspond to the conceptual model of therapeutic persuasiveness. Each theme in the program comprises a learning phase followed by a 1-2 week focusing phase.~Accordingly, the program utilizes the following features:~1. Call to action: Parents receive timely triggers via text messages that are related to the specific goals and therapeutic activities of the modules they have completed.~2. Monitoring and ongoing feedback of user state: Specific practices currently taught are documented within the system through a brief daily report, on which parents receive feedback.~3. Adaptation to user state: Parents' reports on their activities are used to acknowledge their success and to suggest additional actions based on the specific goals reported by parents. Effort related to desired therapeutic activities is adapted based on graded tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPT-STD
Description: This intervention is similar in its features to other programs that deliver DPT, and is suitable for use on computers or on mobile devices. An icon is positioned on the mobile device home screen in order to enable quick access to the program. The DPT-STD comprises seven 10- to 25-minute modules, each corresponding to one of the themes mentioned above. Each module's content includes videos and texts guiding the parent through the training process, and interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials and a questions and answers section that contains frequently asked questions.
Study: NCT06164106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Crisis Response Planning
Description: Individuals complete a chat-based experimental collaborative suicide intervention virtually.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Crisis Response Planning
Description: Individuals complete a collaborative suicide intervention in-person.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crisis Risk Counseling
Description: Individuals complete a standard crisis risk management intervention.
Study: NCT06592287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab + Apatinib + Lrinotecan liposome
Description: Adebrelimab 1200 mg, iv. q3w~Apatinib 250 mg po qd~Lrinotecan liposome 80mg/m2, iv. q3w~Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab + Apatinib + Lrinotecan liposome
Description: Adebrelimab 1200 mg, iv. q3w~Apatinib 250 mg po qd~Lrinotecan liposome 80mg/m2, iv. q3w~Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years.
Study: NCT06593080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The comprehensive TDA based approach
Description: The intervention consists of implementing a comprehensive TDA-based approach for TB diagnosis and treatment decision-making, including shorter treatment for non-severe TB in children identified as TB presumptive cases through a CDSS. It will also include the management of high-risk groups. In practice, all sick children will be assessed using the WHO-suggested TDAs A with CXR (DH) and B without CXR (PHC). CLHIV and those hospitalised with SAM at DH will have further assessment and treatment decisions based on the PAANTHER and TB-Speed SAM TDAs, respectively.~Clinical and microbiological assessment data will be incorporated into a CDSS to help with the clinical decision to initiate TB treatment. The CDSS will incorporate specific features and test results for high-risk group children based on the PAANTHER TDA and the TB-Speed SAM TDA and will incorporate the results of the severity assessment to guide the choice of TB treatment duration once children are diagnosed with TB.
Study: NCT06593262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: app-based digital cognitive behavioral therapy for insomnia with AI chatbot
Description: digital cognitive behavioral therapy for insomnia with two-way interactive, intelligent, and patient-centered conversational agents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: app-based digital cognitive behavioral therapy for insomnia without AI chatbot
Description: digital cognitive behavioral therapy for insomnia without two-way interactive, intelligent, and patient-centered conversational agents
Study: NCT06599944

Intervention type: DIAGNOSTIC_TEST
Intervention: Negative Attitude Scale towards Immigrant Individuals and Cultural Intelligence Scale
Description: Negative Attitude towards Immigrant Individual and Cultural Intelligence scales will be applied to the students in both groups included in the study. Thus, to measure the change in negative attitudes towards immigrant individuals and cultural intelligence as a result of the practice in the migrant health centre.

Intervention type: DIAGNOSTIC_TEST
Intervention: Negative Attitude Scale towards Immigrant Individuals and Cultural Intelligence Scale
Description: Negative Attitude towards Immigrant Individual and Cultural Intelligence scales will be applied to the students in both groups included in the study. Thus, to measure the change in negative attitudes towards immigrant individuals and cultural intelligence as a result of the practice in the migrant health centre.
Study: NCT06603701

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bioimpedancemetry
Description: 2. Bioimpedancemetry at T1, T2, T3 ; the measurement will be~1. Squeletic mass (total and for each of the 4 limbs)~2. Angle phase (total and for each of the 4 limbs)

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamometry
Description: Dynamometry will be performed to assess the strength of each upper limb (deficient and non deficient) at T1, T2, T3
Study: NCT06590142

Intervention type: PROCEDURE
Intervention: Observational study of tissue specimens
Description: No intervention will be made

Intervention type: PROCEDURE
Intervention: Observational study of tissue specimens
Description: No intervention will be made

Intervention type: PROCEDURE
Intervention: Observational study of tissue specimens
Description: No intervention will be made
Study: NCT06594185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista Aspire EA or Aspire Toric ETA IOLs
Description: enVista Aspire EA or Aspire Toric ETA IOLs
Study: NCT06536673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to reduce infectious complications of peritoneal dialysis
Description: * Before catheter placement: The nurse and doctor provide the patient and/or caregiver with a PD simulation.~* Initial training: from the placement of the catheter to the beginning of the technique at home, approximately 4 weeks, 6 and 7 sessions, duration 1-2 hours per session. Individualized learning taking into account learning abilities and education. It includes the explanation of the PD and the display of informational pictograms/capsules.~* Step-by-step teaching: peritoneal exchange, peritoneal orifice care, administration of intraperitoneal medication, recording of constants, detection of complications and risk behaviors.~* Nutritional education and water intake.~* Administration of the Objective Structured Assessment (OSA) checklist.~* Retraining: between the 1st and 3rd month of the start, after an episode of peritonitis and/or hospitalization, risk behaviors, functional/cognitive impairment, passivity/demotivation behaviors, and regularly once the year.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Data collection from the patient's clinical history
Description: Data collection from the patient's clinical history because this new standardized educational intervention was not used.
Study: NCT06211361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Physical exercise intervention within a cardiac rehabilitation program, lasting 2 months, 3 days per week. The intervention consists of a first part of warm up the large muscle groups, accompanied by breathing exercises, followed by a part of strength and muscular resistance training exercises (upper and lower limbs and abdominal muscles), another part of aerobic exercise part (continuous and interval), using a treadmill or cycle ergometer, and finally a part of stretching exercises and a cool-down phase.
Study: NCT06414369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diathermy
Description: A DT equipment (CET 400 VA - RET 130 Watts - Winback, France), with a frequency of 500 kHz and intensity at 40% will be used. It will be applied utilizing a flat capacitive head 4 cm in diameter. It will be applied using longitudinal and transverse movements and a conductive cream for DT. DT will be used over the TP of the right and left trochanteric prominence. The settings will be calibrated so that patients fell no more than mild warmth during the treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simulated Diathermy
Description: This same intervention that has been given to the experimental group, will be simulated as placebo in the control group; the DT will not be activated during administration.
Study: NCT05016531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Focused Ultrasonic Stimulation
Description: Brain stimulation using ultrasonic stimulation in a sequence of increasing intensity (sham, 1 W/CM2, 2 W/CM2, 4 W/CM2, 6 W/CM2, 8 W/CM2)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Focused Ultrasonic Stimulation Frequency
Description: Brain stimulation using ultrasonic stimulation of intensity level determined from intervention 1 at progressively increasing frequency levels (0.35 MHz; 0.5 MHz; 0.75 MHz, 1.0 MHz and 1.5 MHz)
Study: NCT06301984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insight GS
Description: The Andromeda Insight Growing System (Insight GS) is intended to treat severe, progressive multi-planar spinal deformities such as early-onset scoliosis while allowing for skeletal growth.~The Andromeda Insight Growing System consists of blades, clamps and pedicle screws used to form a distinct spinal construct in growing children. The implanted blade is used to brace the spine during growth and minimize the progression of scoliosis. The components are implanted from a posterior approach and are made from Titanium alloy (Ti6AL-4V-ELI), and High Density Polyethylene (HDPE).
Study: NCT05337358

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endocrown
Description: endocrown

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endocrown
Description: endocrown
Study: NCT06463925

Intervention type: OTHER
Group type: OTHER
Intervention: acneic participants group
Description: Application of Effaclar Duo+M to the face and trunk twice daily (morning and evening) after washing with the cleansing gel.
Study: NCT05345808

Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone Acetonide
Description: Triamcinolone Acetonide formulated with chondroitin sulfate and sodium hyaluronate
Study: NCT05730062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride
Description: Oxycodone 10 mg IR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride
Description: Oxycodone 10 mg IR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study: NCT06181331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eConquerFear
Description: The key goals of this e-intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealthMaintenance
Description: eHealthMaintenance is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ConquerFear
Description: ConquerFear is an intensive version of eConquerFear, which consists of 6 face-to-face therapist-led sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eConquerFear+eHealthMaintenance
Description: The combination of eConquerFear and eHealthMaintenance interventions, that consists of 10 weekly online modules.
Study: NCT06121167

Intervention type: DIAGNOSTIC_TEST
Intervention: urinary partial oxygen pressure
Description: arterial blood gas

Intervention type: DIAGNOSTIC_TEST
Intervention: urinary partial oxygen pressure
Description: arterial blood gas
Study: NCT06243861

Intervention type: BEHAVIORAL
Intervention: Mother-child bond
Description: assessing whether the mother-child bond is degraded in the UK, in comparison with that of mothers in post-natal care

Intervention type: BEHAVIORAL
Intervention: Mother-child bond
Description: assessing whether the mother-child bond is degraded in the UK, in comparison with that of mothers in post-natal care
Study: NCT05367154

Intervention type: PROCEDURE
Intervention: Small incision lenticule extraction
Description: Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (WNY, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
Study: NCT06415565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Methods applied as conventional physiotherapy methods are: hotpack, Transcutaneous electrical nerve stimulation and ultrasound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: Methods applied as conventional physiotherapy methods are: hotpack, Transcutaneous electrical nerve stimulation and ultrasound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic mobilization methods
Description: Methods applied as conventional physiotherapy methods: hotpack, Transcutaneous electrical nerve stimulation and ultrasound applications will be applied. Also within the scope of thoracic mobilization: thoracic region extension stretching in the kneeling position, thoracic flexion in the crawling position, halo exercise, thoracic rotation exercises in the crawling position, thoracic rotation in the side lying position. , quadruped extension and rotation exercises will be applied. Patients will be informed that these exercises can also be done as home exercises and they will be asked to practice for 8 weeks.
Study: NCT06227143

Intervention type: PROCEDURE
Intervention: Anesthesia depth monitoring
Description: Anesthesia depth monitoring during opioid-free anesthesia

Intervention type: PROCEDURE
Intervention: Anesthesia depth monitoring
Description: Anesthesia depth monitoring during opioid-free anesthesia

Intervention type: PROCEDURE
Intervention: Anesthesia depth monitoring
Description: Anesthesia depth monitoring during opioid-free anesthesia
Study: NCT05712122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stellate block
Description: stellate blockade effect on Ventricular arrytmia
Study: NCT06096987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic medical record portal videos
Description: Teen to teen videos reviewing information about electronic medical record portals and information shared in electronic medical record portals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General adolescent health videos
Description: Teen to teen videos reviewing information about general adolescent health issues.
Study: NCT04912271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron transdermal patch
Description: Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant
Description: Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, one of the glucocorticoids, has been suggested as a first-line drug for preventing low-level emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone, one of the glucocorticoids, has been suggested as a first-line drug for preventing low-level emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting.
Study: NCT06597708

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: keto diet
Description: They were advised to eat ad libitum but to limit their carbohydrate intake to a maximum of 20-40 g/day to derive at leasut 75%, 15-20%, and 5-10% of total energy from fats, protein, and carbohydrates, respectively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: intermittent fasting with calorie restriction
Description: The 16/8 TRF group was asked to consume their daily calorie intake during an 8-hour window during the daytime and then fast for the remaining 16 hours each day throughout the intervention period.
Study: NCT06586775

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: complete pulpotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: complete pulpotomy
Study: NCT06586671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral administration
Study: NCT06591299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
Study: NCT06593795

Intervention type: PROCEDURE
Intervention: ultrasound
Description: before ECV procedure, an ultrasound will be performed to evaluate~* fetal biometry (BPD, HC, AC, FL, EFW);~* Occiput position (right, left);~* Back position (anterior, posterior, right, left);~* Breech variant (footling, frank, complete);~* Fetal leg posture (extended, flexed)~* Placental localization;~* Amniotic Fluid Index (AFI);~* Fore-bag of amniotic fluid;~* Eventual presence of nuchal cords;~* Fetal head ballottement (yes, no);~* Occiput-spine angle These parameters will be compared to find predictive factors for successful ECV
Study: NCT06590870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The fentanyl solution for administration will be prepared by diluting 2 mL of fentanyl 50 µg/mL with 8 mL of normal saline (bacteriostatic 0.9% sodium chloride) for a fentanyl solution of 10 µg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The normal saline solution for administration will be bacteriostatic 0.9% sodium chloride.
Study: NCT05270759

Intervention type: DIAGNOSTIC_TEST
Intervention: Estimated absolute blood volume
Description: Baseline absolute blood volume will be inferred based on the change in relative blood volume (RBV) after a single 240mL replacement fluid infusion and then monitored throughout the session via the RBV value.

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified VExUS evaluation
Description: The presence of at least 2/3 abnormal venous Doppler waveforms at the following sites: Portal vein, hepatic vein, and femoral vein.
Study: NCT06602687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICSI
Description: The PICSI® dish is a CE marked medical device containing dots of a HA hydrogel (Cooper Surgical).